Abbott Laboratories (NYSE:ABT) received an upgrade from Jefferies, which raised its rating to Buy from Hold, stating that the ...

ABT beats on Q2 earnings and revenues with double-digit growth in Medical Devices, yet shares fall 5% pre-market.

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Abbott Laboratories’ Debt totaled $15 Bil at the end of the latest quarter, while its market capitalization stands at $233 ...

Abbott Laboratories stock tumbled Thursday after the maker of medical devices and nutrition products narrowed its full-year ...

Abbott Laboratories has a lower P/E than the aggregate P/E of 53.67 of the Health Care Equipment & Supplies industry. Ideally ...

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company’s management, portfolio, cash flow, capital return, and pipeline are why. The stock ...

The week is set to be active with various corporate actions, including several companies going ex-trade for dividends, bonus ...

Investing.com -- Jefferies upgraded Abbott Laboratories (NYSE: ABT) to Buy from Hold, calling the market reaction to the ...

Barclays analyst Matt Miksic maintained an Overweight rating and increased the price target from $158 to $159 on April 17, ...